Key result
Rivaroxaban was non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation, and reduced intracranial and fatal bleeding.
Why the study?
Does rivaroxaban prevent stroke or systemic embolism compared to warfarin in patients with atrial fibrillation?
RCT
Does rivaroxaban prevent stroke or systemic embolism compared to warfarin in patients with atrial fibrillation?
Rivaroxaban is non-inferior to warfarin for stroke prevention in atrial fibrillation and is associated with lower rates of intracranial and fatal bleeding.
Answers are grounded in this paper and cite their sources.
Rivaroxaban may offer an alternative to warfarin in atrial fibrillation with lower intracranial bleeding; leaves open confirmation in randomized trials.
P = 0.44), with significant reductions in intracranial haemorrhage (0.5% vs 0.7%, P = 0.02) and fatal bleeding (0.2% vs 0.5%, P = 0.003) in the rivaroxaban group. Conclusion:In patients with AF, rivaroxaban was non-inferior to warfarin for the prevention of stroke or systemic embolism.There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group.2. Apixaban versus warfarin in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Niteen Deshpande (2012) conducted an RCT in Atrial fibrillation. Rivaroxaban vs. Warfarin was evaluated on Stroke or systemic embolism. Rivaroxaban was non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation, and reduced intracranial and fatal bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: